Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Feb 16, 2024
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Verve Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Feb 14
| |||||||
Relay Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
May 31
| |||||||
Verve Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Feb 14
| |||||||
Verve Therapeutics, Inc.
|
0
|
$17.52 | -$1,613,122.14 |
—
| 317.84K |
Oct 3
|
Scheduled
| ||||||
Verve Therapeutics, Inc.
|
0
|
$15.65 | -$1,425,500.00 |
—
| 317.84K |
Aug 10
|
Scheduled
| ||||||
Relay Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jul 25
| |||||||
Relay Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Verve Therapeutics, Inc.
|
0
|
$15.65 | -$1,425,500.00 |
—
| 317.84K |
Jul 19
|
Scheduled
| ||||||
Verve Therapeutics, Inc.
|
0
|
—
|
—
|
—
| 558.84K |
Jul 7 - Jul 12
| |||||||
Verve Therapeutics, Inc.
| 69.67K |
$2.87 | $199,964.38 | +17.08% | 477.52K |
Mar 18
| |||||||
Verve Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Feb 11
| |||||||
Verve Therapeutics, Inc.
|
0
|
$20.65 | -$72,013.70 |
—
| 406.54K |
Jan 4
|
Scheduled
| ||||||
Verve Therapeutics, Inc.
|
0
|
$20.78 | -$1,887,851.21 |
—
| 406.54K |
Dec 27 - Dec 28
|
Scheduled
| ||||||
Verve Therapeutics, Inc.
|
0
|
$20.35 | -$4,322,143.83 |
—
| 406.54K |
Dec 22 - Dec 23
|
Scheduled
| ||||||
Verve Therapeutics, Inc.
| 2.5K |
$19.00 | $47,500.00 | +0.62% | 406.54K |
Jun 17 - Jun 21
| |||||||
Verve Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||